GLP-1 Therapy by Condition in India
Evidence-based guidance on how GLP-1 receptor agonists (semaglutide, tirzepatide) help across the major Indian-population conditions: PCOS, type 2 diabetes, prediabetes, fatty liver (NAFLD/MASLD), hypertension, and obstructive sleep apnea. Each page covers Indian guideline eligibility, trial evidence, brand options, and the patient pathway.
Not sure which applies to you?
The 5-min Indian-guideline check covers BMI + comorbidities at once.
PCOS
GLP-1 Therapy for PCOS in India — What the Evidence Shows
Does GLP-1 (Ozempic, Wegovy, semaglutide, tirzepatide) help PCOS in India? Evidence on weight loss, insulin resistance, menstrual regularity, and fertility. Indian-guideline eligibility and the prescription pathway.
FAQs
7
Type 2 Diabetes
GLP-1 Therapy for Type 2 Diabetes in India — Indian Guideline Use
GLP-1 therapies (Ozempic, Mounjaro, semaglutide, tirzepatide) for type 2 diabetes in India. RSSDI/ESI guideline use, HbA1c reduction evidence, cardiovascular benefits, and the prescription pathway.
FAQs
7
Prediabetes
GLP-1 Therapy for Prediabetes in India — Evidence and Considerations
Should you take GLP-1 for prediabetes in India? Evidence on reversing insulin resistance, preventing T2D progression, and Indian-guideline eligibility. Cost, pathway, and brand options.
FAQs
7
Fatty Liver (NAFLD/MASLD)
GLP-1 Therapy for Fatty Liver (NAFLD/MASLD) in India
GLP-1 therapy for non-alcoholic fatty liver disease (NAFLD/MASLD) in India. Semaglutide and tirzepatide evidence on liver fat, fibrosis, and metabolic outcomes. Indian-guideline eligibility, brand options, and pathway.
FAQs
7
Hypertension
GLP-1 Therapy and Hypertension in India — What to Know
GLP-1 therapy and hypertension in India — evidence on blood pressure reduction, cardiovascular outcomes, and combined BP + obesity management. Indian-guideline eligibility and pathway.
FAQs
7
Obstructive Sleep Apnea
GLP-1 Therapy for Sleep Apnea (OSA) in India — Evidence
GLP-1 therapy for obstructive sleep apnea (OSA) in India — SURMOUNT-OSA evidence for tirzepatide (Mounjaro), Indian-guideline eligibility, and the prescription pathway. Weight loss + CPAP integration.
FAQs
7
Educational content based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT, SCALE, SURMOUNT-OSA), and Indian clinical guidelines (RSSDI, ESI, INASL). Not a substitute for clinical judgment. All GLP-1 therapies are Schedule H drugs in India.